Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Cytochrome P-450 3A and 2D6 Catalyze OrthoHydroxylation of 4-Hydroxytamoxifen and 3-Hydroxytamoxifen (Droloxifene) Yielding Tamoxifen Catechol: Involvement of Catechols in Covalent Binding to Hepatic Proteins

Shangara S. Dehal and David Kupfer
Drug Metabolism and Disposition June 1999, 27 (6) 681-688;
Shangara S. Dehal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Kupfer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Earlier study suggested that 3,4-dihydroxytamoxifen (tam catechol), a tamoxifen metabolite, is proximate to the reactive intermediate that binds covalently to proteins and possibly to DNA (Dehal and Kupfer, 1996). The current study demonstrates that rat and human hepatic cytochrome P-450s (CYPs) catalyze tam catechol formation from tamoxifen (tam), 3-hydroxy-tam (Droloxifene), and 4-hydroxy-tam (4-OH-tam). Higher levels of catechol were formed from 4-OH-tam and 3-hydroxy-tam than from tam. Evidence that human hepatic CYP3A4 and 2D6 catalyze the formation of tam catechol from 4-OH-tam and supportive data that the catechol is proximate to the reactive intermediate, was obtained: 1) There was a good correlation (r = 0.82; p ≤ .0004) between steroidal 6β-hydroxylase (CYP3A activity) andortho hydroxylation of 4-OH-tam in human liver microsomes; 2) monospecific antibodies against CYP3A4 strongly inhibited catechol formation from 4-OH-tam and its covalent binding to proteins in human liver microsomes; 3) low levels of ketoconazole inhibited catechol tam accumulation and covalent binding of 4-OH-tam to human liver proteins; 4) among human P-450s expressed in insect cells (supersomes), only CYP3A4 and 2D6 noticeably catalyzed catechol formation, and cytochrome b5 markedly stimulated the CYP3A4 catalysis; and 5) human livers with high CYP3A and low or high CYP2D6 activity exhibited high catechol formation and those with low 3A and 2D6 activities formed only little catechol. These findings demonstrate that CYP3A4 and to a lesser extent 2D6 catalyze tam catechol formation and support the participation of tam catechol in covalent binding to proteins.

Footnotes

  • Send reprint requests to: Dr. David Kupfer, Ph.D., Department of Pharmacology and Molecular Toxicology, University of Massachusetts Medical Center, 55 Lake Ave. N., Worcester, MA 01655. E-mail: david.kupfer{at}ummed.edu

  • This study was made possible by United States Public Health Service Grant ES00834 from the National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH), and its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIEHS, NIH. A preliminary account of a portion of this study was presented at the American Association for Cancer Research meeting in San Diego, CA. [ (1997) Proc Am Assoc Cancer Res38:3997.]

  • ↵2 Because 3,4-di-OH-tam catechol is not an end product of tam metabolism, but is further transformed and thus cannot be accurately assessed by chemico/physical means, we used a method that permits methylation of the formed catechol in situ, using endogenous or exogenous COMT and 3H-SAM, and the resulting radiolabeled catechol is quantified by scintillation spectroscopy. The value for catechol formation may represent an underestimation, because of competing oxidative reaction resulting in formation of quinones. However, if the rate of catechol oxidation is much slower than the COMT-mediated methylation, then catechol underestimation would be insignificant.

  • Abbreviations used are::
    tam
    tamoxifen [Z-1-(4-(2-dimethylaminoethoxy)-phenyl]-1,2-diphenyl-1-butene]
    4-OH-tam
    4-hydroxy-tamoxifen
    3,4-di-OH-tam
    3,4-dihydroxy-tamoxifen (tam catechol)
    3-OH-tam
    3-hydroxy-tamoxifen (Droloxifene)
    CYP
    cytochrome P-450
    TPE
    triphenylethylene
    SAM
    S-adenosyl-l-methionine iodide salt
    COMT
    catechol-O-methyltransferase
    PB
    phenobarbital
    TAO
    troleandomycin
    Dex
    dexamethasone
    KZ
    ketoconazole
    RI
    reactive intermediate
    DTT
    dithiothreitol
    [3H]-SAM
    [3H-methyl]-S-adenosyl-l-methionine
    TLC
    thin-layer chromatography
    IIAM
    International Institute for the Advancement of Medicine
    • Received December 16, 1998.
    • Accepted February 24, 1999.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 27 (6)
Drug Metabolism and Disposition
Vol. 27, Issue 6
1 Jun 1999
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Cytochrome P-450 3A and 2D6 Catalyze OrthoHydroxylation of 4-Hydroxytamoxifen and 3-Hydroxytamoxifen (Droloxifene) Yielding Tamoxifen Catechol: Involvement of Catechols in Covalent Binding to Hepatic Proteins
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Cytochrome P-450 3A and 2D6 Catalyze OrthoHydroxylation of 4-Hydroxytamoxifen and 3-Hydroxytamoxifen (Droloxifene) Yielding Tamoxifen Catechol: Involvement of Catechols in Covalent Binding to Hepatic Proteins

Shangara S. Dehal and David Kupfer
Drug Metabolism and Disposition June 1, 1999, 27 (6) 681-688;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Cytochrome P-450 3A and 2D6 Catalyze OrthoHydroxylation of 4-Hydroxytamoxifen and 3-Hydroxytamoxifen (Droloxifene) Yielding Tamoxifen Catechol: Involvement of Catechols in Covalent Binding to Hepatic Proteins

Shangara S. Dehal and David Kupfer
Drug Metabolism and Disposition June 1, 1999, 27 (6) 681-688;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • A PBPK model for CBD in adults and children
  • Olanzapine Glucuronidation in Humanized Mice
  • rs2242480 Regulates the Expression of CYP3A4 and CYP3A5
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics